Dexcom appoints Stanford’s Euan Ashley to board of directors

SAN DIEGO - Dexcom, Inc. (NASDAQ:DXCM), a glucose biosensing technology company with a market capitalization of $27.69 billion and an "GREAT" financial health rating according to InvestingPro, announced Monday the appointment of Dr. Euan Ashley to its Board of Directors, effective October 24, 2025.

Ashley currently serves as Chair of the Department of Medicine at Stanford University, where he oversees 15 divisions and more than 800 faculty members. His research background spans precision medicine, data science, artificial intelligence, and digital health. The appointment comes as Dexcom maintains strong financial performance, with annual revenues of $4.3 billion and a healthy gross margin of 58.77%.

In addition to his academic role, Ashley has co-founded seven biotechnology companies and co-directs Stanford’s Catalyst program, which invests in biomedical innovations. He also serves on the Board of Directors of AstraZeneca Plc.

"Dexcom is well-positioned to advance metabolic health and improve quality of life for millions of people globally," said Jake Leach, president and interim CEO at Dexcom, in a press release statement.

Ashley received his medical degree from the University of Glasgow and a doctorate from the University of Oxford, with cardiology training completed at Stanford University.

Dexcom, founded in 1999, develops glucose monitoring technology for diabetes management. The company describes itself as having "pioneered and set the standard in glucose biosensing for more than 25 years." With its upcoming earnings report scheduled for October 30, 2025, investors can access detailed analysis and 10 additional ProTips through InvestingPro’s comprehensive research reports, which transform complex Wall Street data into actionable intelligence.

The appointment follows the departure of Eric Topol from the Dexcom Board. Topol, Director of the Scripps Translational Science Institute, noted that Ashley was "at the top of my list" of potential replacements.

In other recent news, DexCom has been the focus of several analyst reports ahead of its upcoming third-quarter earnings release. TD Cowen has maintained its Buy rating with a price target of $100, expressing confidence in the resolution of earlier issues with the G7 continuous glucose monitoring system. Piper Sandler also reiterated an Overweight rating and a $100 price target, suggesting that the market setup for DexCom shares is favorable despite investor concerns. Stifel resumed coverage with a Buy rating, setting a price target of $85, and highlighted the potential of DexCom’s G7 15-day sensor in the Type 2 diabetes segment.

UBS defended its Buy rating and set a higher price target of $106, despite recent market concerns over the G7 sensor’s reliability. The firm noted increased MAUDE events and injuries related to the G7 sensor, which have contributed to bearish sentiment. However, TD Cowen’s analysis indicated that most deployment and accuracy issues with the G7 device have been resolved. These developments showcase a range of analyst perspectives on DexCom’s potential performance and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.